ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Provention Bio, Inc. Investors with Losses to Secure Counsel Before Important July 20 Deadline – PRVB
WHY: Rosen Law Firm, a global investor rights law firm, is pleased to announce that it has filed a class action lawsuit on behalf of buyers of Provention Bio, Inc. (NASDAQ: PRVB) securities between November 2, 2020 and April 8, 2021. inclusive (the “lesson”). A class action lawsuit has already been filed. If you want to stand as the lead plaintiff, you must transfer the court by July 20, 2021 at the latest.
SO WHAT: If you purchased Provention Bio securities during the class period, you may be eligible for compensation without paying any out-of-pocket expenses or expense through a contingent fee agreement.
WHAT TO DO NEXT: To participate in Provention Bio’s class action lawsuit, go to http://www.rosenlegal.com/cases-register-2101.html or call Phillip Kim, Esq. toll free at 866-767-3653 or email [email protected] or [email protected] for class action information. A class action lawsuit has already been filed. If you want to serve as the lead plaintiff, you must transfer the court no later than July 20, 2021. A lead plaintiff is a representative party who acts on behalf of other class members in directing the dispute.
WHY ROSEN LAW: We encourage investors to select skilled advisors with a track record in leadership roles. Companies that issue notices often lack comparable experience or resources. Rosen law firm represents investors around the world and focuses on class action and shareholder derivatives litigation. Law firm Rosen has filed its largest class action lawsuit against a Chinese company to date. Rosen law firm was ranked # 1 by ISS Securities Class Action Services for number of class action settlements in 2017. The firm has been in the top 4 every year since 2013 and has collected hundreds of millions of dollars on investors. In 2019 alone, the company raised more than $ 438 million for investors. In 2020, founding partner Laurence Rosen was named the Titan of Plaintiffs’ Bar by Act 360. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.
The story goes on
CASE DETAILS: According to the lawsuit, throughout the class, the defendants made false and / or misleading statements and / or failed to disclose that: (1) the Teplizumab Biologics License Application (“BLA”) as filed was and would be defective require additional data to obtain US Food and Drug Administration approval; (2) Accordingly, the teplizumab BLA lacked the proven support that the Company had led investors to believe it possessed. (3) Provention Bio had therefore overestimated the approval prospects for teplizumab BLA and thus the schedule for marketing teplizumab. and (4) as a result, the defendants’ public statements at all relevant times have been materially false and misleading. When the real details hit the market, the lawsuit alleged that investors suffered damage.
To participate in Provention Bio’s class action lawsuit, go to http://www.rosenlegal.com/cases-register-2101.html or call Phillip Kim, Esq. toll free at 866-767-3653 or email [email protected] or [email protected] for class action information.
No class has been certified. Until a class is certified, you will not be represented by an attorney unless you keep one. You can choose an attorney of your choice. You can also remain an absent class member and do nothing at this point. An investor’s ability to participate in a possible future recovery does not depend on whether they are the lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https: // www. facebook .com / rosenlawfirm /.
Lawyer advertising. Previous results do not guarantee a similar result.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210530005018/de/
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen, PA law firm
275 Madison Avenue, 40th floor
New York, NY 10016
Tel .: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827